Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2823-2831

  Richards, Donald ^a,b   Kocs, Darren M ^a,b   Spira, Alexander I ^a,c   David McCollum, A ^a,d   Diab, Sami ^a,e   Hecker, Lanny I ^a,f   Cohn, Allen ^a,e   Zhan, Feng ^a   Asmar, Lina ^a  

^a US Oncology Research   (United States)

^b TEXAS ONCOLOGY   (United States)

^c Virginia Cancer Specialists   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e ROCKY MOUNTAIN CANCER CENTERS   (United States)

^f Arizona Oncology Associates   (United States)

Author keywords

Adenocarcinoma; Drug therapy; Gastroesophageal junction; KRAS

Indexed keywords

CETUXIMAB; DOCETAXEL; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; DRUG THERAPY; GASTROESOPHAGEAL JUNCTION; KRAS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; STOMACH NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84881099408     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.022     Document Type: Article

References (39)

1. D.Y. Kim, J.K. Joo, S.Y. Dyu, Y.K. Park, Y.J. Kim, and S.K. Kim Clinocopathological characteristics of patients with proximal third gastric cancer Acta Chir Gelg 104 6 2004 677 682
2. C. Louvet, T. Andre, and J.M. Tigaud Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 23 2002 4543 4548
3. A.D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W.E. Fleig Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 18 2006 2903 2909
4. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 31 2006 4991 4997
5. S.E. Al-Batran, A. Atmaca, and S. Hegewisch-Becker Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 22 4 2004 658 663
6. A.M. Mauer, E.H. Kraut, and S.A. Krauss Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus Ann Oncol 16 8 2005 1320 1325
7. F. De Vita, M. Orditura, and E. Matano A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients Br J Cancer 92 9 2005 1644 1649
8. K. Sumpter, C. Harper-Wynne, and D. Cunningham Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF Br J Cancer 92 11 2005 1976 1983
9. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogstric cancer N Engl J Med 358 1 2008 36
10. D. Richards, D. McCollum, and L. Wilfong Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction Ann Oncol 19 2008 104 108
11. R. Kopp, M. Ruge, and E. Rothbauer Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients Anticancer Res 2 2B 2002 1161 1167
12. I. Garcia, F. Vizoso, and A. Martin Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer Ann Surg Oncol 10 3 2003 234 241
13. S. Tejpar, M. Peeters, and Y. Humblet Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) J Clin Oncol 26 2008 (May 20 Suppl.; abstr. 4001)
14. A. Achmad, H. Hanaoka, and H. Yoshioka Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using (64) Cu-labeled cetuximab positron emission tomography Cancer Sci 2011 10.1111/j.1349-7006.2011. 02166.x [Epub ahead of print]
15. E. Van Cutsem, I. Lang, and G. D'haens KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Clin Oncol 26 2008 (May 20 Suppl.; abstr. 2)
16. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BM099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;29:918-27.
17. National Cancer Institute's Cancer Therapy Evaluation Program (NCI CTEP) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. August 9, 2006.
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization of Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. C. Pinto, F. Di Fabio, and S. Siena Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 2007 510 517 [Epub 2006 Dec 12]
20. S.W. Han, D.Y. Oh, and S.A. Im Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6 Cancer Sci 101 2010 793 799 [Epub 2009 Nov 23]
21. J.A. Chan, L.S. Blaszkowsky, and P.C. Enzinger A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Ann Oncol 22 2011 1367 1373 [Epub 2011 Jan 7]
22. P.J. Gold, B. Goldman, and S. Iqbal Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415) J Thorac Oncol 5 2010 1472 1476
23. D. Richards, D. McCollum, and L. Wilfong Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction Ann Oncol 19 2008 104 108 [Epub 2007 Sep 25]
24. T.S. Waddell, I. Chau, and Y. Barbachano A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) J Clin Oncol 30 2012 (Suppl.; abstr. LBA4000)
25. Lordick F. EXPAND: Erbitux in combination with Xeloda and cisplatin in advanced esophagogastic cancer. European Society for Medical Oncology (ESMO). Vienna 2012 App, Vienna 2012 Congress. 09/30/2012.
26. S.J. Dutton, J.M. Blazeby, and R.D. Russell Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefiitinib (COG) J Clin Oncol 30 2012 (Suppl. 34; abstr. 6)
27. J.M. Roca, V. Alonso, and C. Pericay Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer Chemotherapy 56 2010 142 146 [Epub 2010 Apr 12]
28. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial Lancet 376 2010 687 697 [Epub 2010 Aug 19]
29. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261 [Epub 2010 Jan 25]
30. S. Velho, C. Oliveira, and A. Ferreira The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 2005 1649 1654
31. D.S. Byun, K. Cho, and B.K. Ryu Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma Int J Cancer 104 2003 318 327
32. S.A. Im, K.E. Lee, and E. Nam Potential prognostic significance of p185(HERs) overexpression with loss of PTEN expression in gastric carcinomas Tumori 91 2005 513 521
33. J. Lee, J.W. Seo, and H.J. Jun Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target Oncol Rep 25 2011 1517 1524 10.3892/or.2011.1219. Epub 2011 Mar 18
34. Y.Y. Janjigian, L.H. Tang, and D.G. Coit MET expression and amplification in patients with localized gastric cancer Cancer Epidemiol Biomarkers Prev 20 2011 1021 1027
35. F. Graziano, N. Galluccio, and P. Lorenzini Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer J Clin Oncol 29 2011 4789 4795
36. S. Heindl, E. Eggenstein, and S. Keller Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines J Cancer Res Clin Oncol 2012 [Epub ahead of print]
37. M. Hayashi, M. Inokuchi, and Y. Takagi High expression of HER3 is associated with a decreased survival in gastric cancer Clin Cancer Res 14 23 2008 7843 7849
38. M.D. Begnami, E. Fukuda, and J.H. Fregnani Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome J Clin Oncol 29 22 2011 3030 3036 10.1200/JCO.2010.33.6313 [Epub 2011 Jun 27]
39. X.L. Zhang, Y.S. Yang, and D.P. Xu Comparative study on overexpression of HER2/neu and HER3 in gastric cancer World J Surg 33 10 2009 2112 2118